APA (7th ed.) Citation

P, G., Ø, H., N, A., NF, A., TG, D., H, G., . . . S, L. (2015). Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Bone marrow transplantation, 50(10), 1306. https://doi.org/10.1038/bmt.2015.125

Chicago Style (17th ed.) Citation

P, Gimsing, et al. "Salvage Bortezomib-dexamethasone and High-dose Melphalan (HDM) and Autologous Stem Cell Support (ASCT) in Myeloma Patients at First Relapse After HDM with ASCT. A Phase-2 Trial." Bone Marrow Transplantation 50, no. 10 (2015): 1306. https://doi.org/10.1038/bmt.2015.125.

MLA (9th ed.) Citation

P, Gimsing, et al. "Salvage Bortezomib-dexamethasone and High-dose Melphalan (HDM) and Autologous Stem Cell Support (ASCT) in Myeloma Patients at First Relapse After HDM with ASCT. A Phase-2 Trial." Bone Marrow Transplantation, vol. 50, no. 10, 2015, p. 1306, https://doi.org/10.1038/bmt.2015.125.